169 related articles for article (PubMed ID: 29879067)
1. A rare subtype of meningioma: Case series of anaplastic meningioma and review of the literature.
Cao H; Jiang B; Zhao Y; Fan C
Medicine (Baltimore); 2018 Jun; 97(23):e11019. PubMed ID: 29879067
[TBL] [Abstract][Full Text] [Related]
2. Metastatic Atypical and Anaplastic Meningioma: A Case Series and Review of the Literature.
Kessler RA; Garzon-Muvdi T; Yang W; Weingart J; Olivi A; Huang J; Brem H; Lim M
World Neurosurg; 2017 May; 101():47-56. PubMed ID: 28143726
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment.
Engenhart-Cabillic R; Farhoud A; Sure U; Heinze S; Henzel M; Mennel HD; Bertalanffy H
Strahlenther Onkol; 2006 Nov; 182(11):641-6. PubMed ID: 17072521
[TBL] [Abstract][Full Text] [Related]
4. Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features.
Yang SY; Park CK; Park SH; Kim DG; Chung YS; Jung HW
J Neurol Neurosurg Psychiatry; 2008 May; 79(5):574-80. PubMed ID: 17766430
[TBL] [Abstract][Full Text] [Related]
5. Malignant transformation of meningioma: Case report.
Qu X; Jiang J; Wang H; Zhang C; Deng Q; Xu X; Zhou S; Yi Y; Qiu L
Medicine (Baltimore); 2023 Mar; 102(13):e33409. PubMed ID: 37000075
[TBL] [Abstract][Full Text] [Related]
6. Emergence of a high-grade sarcoma in a recurrent meningioma: malignant progression or collision tumor?
Oz B; Pekmezci M; Dashti R; Karaman K; Kuday C; Tihan T
Arch Pathol Lab Med; 2011 Jul; 135(7):935-40. PubMed ID: 21732786
[TBL] [Abstract][Full Text] [Related]
7. Clear cell meningioma with anaplastic features: case report and review of literature.
Tong-tong W; Li-juan B; Zhi L; Yang L; Bo-ning L; Quan H
Pathol Res Pract; 2010 May; 206(5):349-54. PubMed ID: 19857933
[TBL] [Abstract][Full Text] [Related]
8. Scalp Invasion by Atypical or Anaplastic Meningioma Is a Risk Factor for Development of Systemic Metastasis.
Garzon-Muvdi T; Maxwell R; Luksik A; Kessler R; Weingart J; Olivi A; Bettegowda C; Tamargo R; Brem H; Lim M
World Neurosurg; 2020 Oct; 142():e133-e139. PubMed ID: 32599198
[TBL] [Abstract][Full Text] [Related]
9. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases.
Roser F; Samii M; Ostertag H; Bellinzona M
Acta Neurochir (Wien); 2004 Jan; 146(1):37-44; discussion 44. PubMed ID: 14740263
[TBL] [Abstract][Full Text] [Related]
10. [Recurrent meningioma with malignant transformation: a case which changed from meningothelial type to papillary type].
Yamazaki Y; Kawano N; Suwa T; Ito H; Yada K; Kuwao S
No Shinkei Geka; 1994 Mar; 22(3):285-9. PubMed ID: 8133973
[TBL] [Abstract][Full Text] [Related]
11. Relationship between malignant subtypes of meningioma and clinical outcome.
Ko KW; Nam DH; Kong DS; Lee JI; Park K; Kim JH
J Clin Neurosci; 2007 Aug; 14(8):747-53. PubMed ID: 17499508
[TBL] [Abstract][Full Text] [Related]
12. Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma.
Bruna J; Brell M; Ferrer I; Gimenez-Bonafe P; Tortosa A
Neuropathology; 2007 Apr; 27(2):114-20. PubMed ID: 17494511
[TBL] [Abstract][Full Text] [Related]
13. Malignant intraventricular meningioma with craniospinal dissemination and concurrent pulmonary metastasis.
Tao CY; Wang JJ; Li H; You C
World J Surg Oncol; 2014 Jul; 12():238. PubMed ID: 25073808
[TBL] [Abstract][Full Text] [Related]
14. Intracranial meningeal tumours in childhood: a clinicopathologic study including MIB-1 immunohistochemistry.
Demirtaş E; Erşahin Y; Yilmaz F; Mutluer S; Veral A
Pathol Res Pract; 2000; 196(3):151-8. PubMed ID: 10729919
[TBL] [Abstract][Full Text] [Related]
15. Recurrence Interval Within 1 Year Leads to Death in Patients with Grade 2 Meningioma.
Ukai R; Wanibuchi M; Komatsu K; Kimura Y; Akiyama Y; Mikami T; Mikuni N
World Neurosurg; 2020 Oct; 142():e58-e65. PubMed ID: 32454195
[TBL] [Abstract][Full Text] [Related]
16. Resected WHO grade I meningioma and predictors of local control.
Nowak-Choi K; Palmer JD; Casey J; Chitale A; Kalchman I; Buss E; Keith SW; Hegarty SE; Curtis M; Solomides C; Shi W; Judy K; Andrews DW; Farrell C; Werner-Wasik M
J Neurooncol; 2021 Mar; 152(1):145-151. PubMed ID: 33420897
[TBL] [Abstract][Full Text] [Related]
17. World Health Organization Grade II Meningioma: A 10-Year Retrospective Study for Recurrence and Prognostic Factor Assessment.
Champeaux C; Dunn L
World Neurosurg; 2016 May; 89():180-6. PubMed ID: 26850975
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic radiotherapy as primary definitive or postoperative treatment of intracranial meningioma of WHO grade II and III leads to better disease control than stereotactic radiotherapy of recurrent meningioma.
Lubgan D; Rutzner S; Lambrecht U; Rössler K; Buchfelder M; Eyüpoglu I; Fietkau R; Semrau S
J Neurooncol; 2017 Sep; 134(2):407-416. PubMed ID: 28667597
[TBL] [Abstract][Full Text] [Related]
19. Early gross recurrence of atypical meningioma.
Stark AM; Buhl R; Mehdorn HM
J Neurooncol; 2005 Nov; 75(2):223-4. PubMed ID: 16132505
[No Abstract] [Full Text] [Related]
20. Atypical Meningiomas: Histologic and Clinical Factors Associated With Recurrence.
Ros-Sanjuan A; Iglesias-Moroño S; Carrasco-Brenes A; Bautista-Ojeda D; Arraez-Sanchez MA
World Neurosurg; 2019 May; 125():e248-e256. PubMed ID: 30684705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
